Virbac Reports Strong H1 Performance With Organic Revenue Growth and Improved EBIT Margin
In the first half of 2026, Virbac reported solid financial performance marked by an organic revenue growth of +7.4% and a robust adjusted EBIT margin of 18.8%. The company's companion animal segment grew by 10%, while its farm animal division increased by 6.7%, driven largely by the Supercharge platforms (excluding Thyronorm), which saw around 12% growth. The revenue increase was supported by a volume/mix effect of approximately +5.4% and price increases contributing ~+2%. The operating margin improved by 0.5 percentage points compared to H1 2025, despite higher operating expenses due to phasing effects between the first and second halves of the year. Consolidated net income rose by 5.9%, reaching €87.1 million. Virbac confirmed its full-year guidance at the upper end of previously stated ranges for revenue growth (between 5.5% and 7.5%) and an adjusted recurring operating margin around 17%. CEO Paul Martingell highlighted the company's strong performance as a reflection of strategic initiatives like 'Supercharge' platforms and seamless integration of Thyronorm, aligning with its long-term 'Growing Together' strategy.
Topics: adjusted EBIT margin organic performance revenue growth